VEGFA and glioblastoma: In this regard, the human monoclonal antibody (mAb) bevacizumab (Bev), that targets vascular endothelial growth factor (VEGF)-A, achieved the approval by the US Food and Drug Administration (FDA) for the treatment of GBM at first relapse after the standard chemoradiation based on the prolonged progression-free survival (PFS) and clinical benefit, such as relief of neurological symptom and reduction of steroids [3–5].